The U.S. Justice Department has sued the owners of a group
of pain management clinics based in Tennessee, alleging that
they billed federal healthcare programs for injections that were
never provided to patients.
A federal judge has refused to certify a class of consumers
who sued India's Ranbaxy Laboratories Ltd to obtain a refund for
generic Lipitor pills they bought that the company later
recalled due to a possible contamination threat.
Atrium Health, which runs the largest hospital network in
North Carolina, has agreed to resolve a U.S. Justice Department
antitrust lawsuit in a nonmonetary deal in which it agreed to
eliminate contractual prohibitions on insurers steering patients
to lower-cost medical providers.
A federal appeals court on Wednesday blocked the U.S.
Centers for Medicare & Medicaid Services from enforcing policies
adopted in 2010 that altered how Medicaid payments to hospitals
that treat high numbers of low-income patients are calculated.
A former State Street Corp executive was sentenced on
Wednesday to six months in prison for participating in a scheme
to overcharge customers of the bank by applying secret
commissions on billions of dollars' worth of securities trades.
A former executive at Insys Therapeutics Inc accused of
participating in a wide-ranging scheme to bribe doctors to
prescribe the company's flagship opioid medication has agreed to
plead guilty, federal prosecutors said on Wednesday.
A former Merrimack Pharmaceuticals Inc employee was
sentenced on Tuesday to six months in prison after being
convicted of participating in an insider trading scheme with a
friend at a rival biopharmaceutical company.
Aveo Pharmaceuticals Inc's ex-chief financial officer, who
is on trial for allegedly misleading investors by hiding bad
news about the biotech's efforts to obtain regulatory approval
for a kidney cancer drug, acknowledged on Tuesday that he never
disclosed that the U.S. Food and Drug Administration had
recommended the drugmaker conduct another clinical trial.
Insys Therapeutics Inc has disclosed it expects one of its
subsidiaries will have to plead guilty as part of an at least
$150 million deal it is negotiating with the U.S. Justice
Department resolving claims the drugmaker paid doctors kickbacks
to prescribe an opioid.
The owner of two Washington state medical research companies
has been indicted on charges that he engaged in a fraudulent
scheme to enrich himself by falsifying data for a drug trial
testing an opioid alternative.